Production and characterization of monoclonal antibodies against highly immunogenic Opisthorchis viverrini proteins and development of coproantigen detection

Arimatsu, Yuji; Teimoori, Salma; Surapaitoon, Arpa; Sripa, Banchob

doi:10.1016/j.molbiopara.2020.111323

Cited by 2 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eight mAbs were raised to surface antigens of Schistosoma japonicum , only one of which was an IgM that conferred protection via passive transfer studies in mice [ 24 ]. An IgG mAb was raised to 78 kDa ES protein-protected mice against challenge infection with the livestock liver fluke Fasciola hepatica [ 25 ], but to the best of our knowledge, mAbs raised against human liver fluke antigens have only been used to develop diagnostic tools [ 26 , 27 , 28 , 29 ] and were not shown to confer protective efficacy in passive transfer studies.…”

Section: Discussionmentioning

confidence: 99%

Monoclonal Antibodies Targeting an Opisthorchis viverrini Extracellular Vesicle Tetraspanin Protect Hamsters against Challenge Infection

et al. 2021

View full text Add to dashboard Cite

Opisthorchis viverrini causes severe pathology in the bile ducts of infected human hosts, and chronic infection can culminate in bile duct cancer. The prevention of infection by vaccination would decrease opisthorchiasis-induced morbidity and mortality. The tetraspanin protein, Ov-TSP-2, is located on the membrane of secreted extracellular vesicles (EVs), and is a candidate antigen for inclusion in a subunit vaccine. To address the role of anti-Ov-TSP-2 antibodies in protection, we assessed the protective capacity of anti-Ov-TSP-2 monoclonal antibodies (mAbs) against opisthorchiasis. Two anti-TSP-2 IgM mAbs, 1D6 and 3F5, and an isotype control were passively transferred to hamsters, followed by parasite challenge one day later. Hamsters that received 3F5 had 74.5% fewer adult flukes and 67.4% fewer eggs per gram of feces compared to hamsters that received the control IgM. Both 1D6 and 3F5 (but not the control IgM) blocked the uptake of fluke EVs by human bile duct epithelial cells in vitro. This is the first report of passive immunization against human liver fluke infection, and the findings portend the feasibility of antibody-directed therapies for liver fluke infection, bolstering the selection of TSPs as components of a subunit vaccine for opisthorchiasis and fluke infections generally.

show abstract